#Tagrisso, a third-generation lung cancer targeting anticancer drug, is once again discussed at the Cancer Drugs Benefit Appraisal Committee in about a year. According to related industries, discussions on expanding the benefits of first-line therapy for the third-generation epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (Osimertinib) will be held at the Cancer Drugs Benefit Appraisal Committee, which will be held on the 7th.

As Leclaza, a drug of the same class, passed the Cancer Drugs Benefit Appraisal Committee within a month after approval, it is noteworthy whether Tagrisso can pass to expand benefits.

Tagrisso was added first-line therapy indications i